N	Concordance
1	vival in patients with locally advanced prostate cancer treated with radiotherap
2	remains to detect clinically aggressive prostate cancer at early stages while mi
3	ion is uncommon in pathological stage C prostate cancer and its presence in prem
4	 man with hormone-refractory (stage D2) prostate cancer was admitted to the hosp
5	ey were at increased risk of developing prostate cancer could not be addressed b
6	ncreased body fat, is a risk factor for prostate cancer through unknown mechanis
7	t dosimetry for patients with low-grade prostate cancer treated with combined US
8	ecently published linkage of hereditary prostate cancer families to chromosome 1
9	   assembly in metastasis-derived human prostate cancer cell lines (LNCaP, PPC-
10	her hand, although androgen-independent prostate cancer cells do not undergo apo
11	 increases with progression of invasive prostate cancer and might in part accoun
12	ival in patients with stages III and IV prostate cancer  compared to hormonal th
13	able patients with clinically localized prostate cancer received definitive radi
14	lly advanced or asymptomatic metastatic prostate cancer showed  better overall s
15	ata for all patients with node-positive prostate cancer diagnosed in our institu
16	taking the drug finasteride can prevent prostate cancer in men ages 55  and olde
17	roliferation rates in locally recurrent prostate cancer after radical prostatect
18	cl-2 expression from hormone-refractory prostate cancer cells and for killing pr